These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33652272)

  • 41. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
    Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
    BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic accuracy and usefulness of the Genotype MTBDRplus assay in diagnosing multidrug-resistant tuberculosis in Cameroon? a cross-sectional study.
    Abanda NN; Djieugoué JY; Lim E; Pefura-Yone EW; Mbacham WF; Vernet G; Penlap VM; Eyangoh SI; Taylor DW; Leke RGF
    BMC Infect Dis; 2017 May; 17(1):379. PubMed ID: 28569148
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic performance of Anyplex II MTB/MDR/XDR for detection of resistance to first and second line drugs in Mycobacterium tuberculosis.
    Pérez-García F; Ruiz-Serrano MJ; López Roa P; Acosta F; Pérez-Lago L; García-De-Viedma D; Bouza E
    J Microbiol Methods; 2017 Aug; 139():74-78. PubMed ID: 28511895
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A low cost, home-made, reverse-line blot hybridisation assay for rapid detection of rifampicin resistance in Mycobacterium tuberculosis.
    Morcillo N; Zumarraga M; Alito A; Dolmann A; Schouls L; Cataldi A; Kremer K; van Soolingen D
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):959-65. PubMed ID: 12475141
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Good, the Bad and the Ugly of the Next-Generation Xpert Mtb/Rif
    García-Basteiro AL; Saavedra B; Cobelens F
    Arch Bronconeumol; 2017 Dec; 53(12):665-666. PubMed ID: 28705388
    [No Abstract]   [Full Text] [Related]  

  • 47. Initial screening of extra-pulmonary tuberculosis using the Xpert MTB/RIF assay improves case detection rates.
    Jain A; Singh PK; Singh U; Kumar V
    Int J Tuberc Lung Dis; 2017 Apr; 21(4):478-480. PubMed ID: 28284274
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of efficiency of nested multiplex allele-specific PCR assay for detection of multidrug resistant tuberculosis directly from sputum samples.
    Mistri SK; Sultana M; Kamal SM; Alam MM; Irin F; Nessa J; Ahsan CR; Yasmin M
    Lett Appl Microbiol; 2016 May; 62(5):411-8. PubMed ID: 26972777
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection and characterization of drug-resistant conferring genes in Mycobacterium tuberculosis complex strains: A prospective study in two distant regions of Ghana.
    Otchere ID; Asante-Poku A; Osei-Wusu S; Baddoo A; Sarpong E; Ganiyu AH; Aboagye SY; Forson A; Bonsu F; Yahayah AI; Koram K; Gagneux S; Yeboah-Manu D
    Tuberculosis (Edinb); 2016 Jul; 99():147-154. PubMed ID: 27450017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene.
    Mathys V; van de Vyvere M; de Droogh E; Soetaert K; Groenen G
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1255-7. PubMed ID: 25216843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs.
    Said HM; Kock MM; Ismail NA; Baba K; Omar SV; Osman AG; Hoosen AA; Ehlers MM
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):104-9. PubMed ID: 22236854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular characterization of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Kazakhstan.
    Kozhamkulov U; Akhmetova A; Rakhimova S; Belova E; Alenova A; Bismilda V; Chingissova L; Ismailov S; Ramanculov E; Momynaliev K
    Jpn J Infect Dis; 2011; 64(3):253-5. PubMed ID: 21617314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-time PCR followed by high-resolution melting curve analysis: A rapid and pragmatic approach for screening of multidrug-resistant extrapulmonary tuberculosis.
    Sharma K; Sharma M; Singh S; Modi M; Sharma A; Ray P; Varma S
    Tuberculosis (Edinb); 2017 Sep; 106():56-61. PubMed ID: 28802406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
    Tan Y; Hu Z; Zhao Y; Cai X; Luo C; Zou C; Liu X
    J Clin Microbiol; 2012 Jan; 50(1):81-5. PubMed ID: 22075601
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Geographical profile of rpoB gene mutations in rifampicin resistant Mycobacterium tuberculosis isolates in Sri Lanka.
    Adikaram CP; Perera J; Wijesundera SS
    Microb Drug Resist; 2012 Oct; 18(5):525-30. PubMed ID: 22731859
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidemiology of molecular probes in Xpert MTB/RIF assay in Khyber Pakhtunkhwa, Pakistan.
    Khan AS; Khan MT; Ali S; Khan TA; Qasim M; Malik A; Ali S; Sajjad W; Ain QU; Irfan M
    Arch Microbiol; 2021 Jul; 203(5):2249-2256. PubMed ID: 33640990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Capacity of Abbott RealTi
    Hofmann-Thiel S; Molodtsov N; Duffner C; Kadyrov A; Kalmambetova G; Kabirov O; Rajabov A; Parpieva N; Sayfutdinov Z; Vogel M; Vogel H; Antonenka U; Hoffmann H
    Int J Tuberc Lung Dis; 2019 Apr; 23(4):458-464. PubMed ID: 31064625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.
    Whitfield MG; Warren RM; Mathys V; Scott L; De Vos E; Stevens W; Streicher EM; Groenen G; Sirgel FA; Van Rie A
    J Antimicrob Chemother; 2018 Oct; 73(10):2667-2674. PubMed ID: 29982641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct rapid diagnosis of rifampicin-resistant M. tuberculosis infection in clinical samples by line probe assay (INNO LiPA Rif-TB).
    Cirillo DM; Piana F; Frisicale L; Quaranta M; Riccabone A; Penati V; Vaccarino P; Marchiaro G
    New Microbiol; 2004 Jul; 27(3):221-7. PubMed ID: 15460524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Xpert(®) MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, Zimbabwe.
    Metcalfe JZ; Makumbirofa S; Makamure B; Sandy C; Bara W; Mason P; Hopewell PC
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):882-9. PubMed ID: 27287639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.